Advancing Education on Biosimilars Act of 2020
Latest action · Dec 18, 2020 Held at the desk.
Progress
Where this bill reached, and when. A stage with no date was not reached; one that failed a vote and later carried shows the date it carried.
- IntroducedMay 23, 2019
- Passed SenateDec 17, 2020
- Passed HouseNot reached
- To the PresidentNot reached
- Became lawNot reached
Summary
Advancing Education on Biosimilars Act of 2020
This bill requires the Food and Drug Administration (FDA) to advance education and awareness among health care providers about biological products as appropriate, including by developing or improving continuing education programs that address the prescribing of biological products and biosimilars. (A biosimilar is a biological product that is highly similar to an FDA-approved reference biological product and has no clinically meaningful differences from that reference product.)
The FDA may also maintain and operate a website to provide educational materials about biological products.
Cosponsors 1
Members who signed on, in the order they did. All signed on May 23, 2019.
| Seat | Cosponsor | Signed on | |
|---|---|---|---|
| D-NH | Margaret Wood Hassan | Original | May 23, 2019 |
Committees 1
Where it was sent and what each committee and subcommittee did with it, in order.
| Chamber | Committee | What it did |
|---|---|---|
| Senate | Health, Education, Labor, and Pensions Committee | Referred May 23, 2019Discharged Dec 17, 2020 |
Actions 8
Everything that happened, newest first.
- Dec 18, 2020Message on Senate action sent to the House.
- Dec 18, 2020Received in the House.
- Dec 18, 2020Held at the desk.
- Dec 17, 2020Senate Committee on Health, Education, Labor, and Pensions discharged by Unanimous Consent.
- Dec 17, 2020Measure laid before Senate by unanimous consent. (consideration: CR S7642-7643)
- Dec 17, 2020Passed/agreed to in Senate: Passed Senate with an amendment by Unanimous Consent. (text of amendment in the nature of a substitute: CR S7643)
- May 23, 2019Introduced in Senate
- May 23, 2019Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
In the Congressional Record 1
Days the Record’s own index lists this bill, newest first, with the pages and the members it names. Pages starting H are the House, S the Senate, E Extensions of Remarks.
| Where | In the Record | Members | Date |
|---|---|---|---|
| Senate | Debate and remarks S7642, S7643Text printed S7643Amendments S7637, S7643 | Lamar Alexander R-TN (amendment), Mike Braun R-IN | Dec 17, 2020 |
Research
What has been written about this bill: committee reports, cost estimates, the sponsor’s authority statement, printed hearings and the Congressional Research Service’s work.
Printed hearings 1
Hearings whose printed record names this bill, newest first: hearings on it, and wider hearings where it came up.
Amendments 1
Amendments offered to this bill.
| Amendment | Description | Offered by | Status |
|---|---|---|---|
| SA 2716 | In the nature of a substitute. | Lamar Alexander R-TN | Amendment SA 2716 agreed to in Senate by Unanimous Consent. |
Titles 3
Every title it has carried, official and short, at each stage.
- Official Title as Introduced
- A bill to educate health care providers and the public on biosimilar biological products, and for other purposes.
- Short Title(s) as Introduced
- Advancing Education on Biosimilars Act of 2019
- Short Title(s) as Passed Senate
- Advancing Education on Biosimilars Act of 2020
Subjects
Assigned by the Library of Congress. Policy area: Health.
Text 2
Each version as it was printed, newest first.
- Dec 17, 2020Engrossed in Senate
- May 23, 2019Introduced in Senate
Everything here is as published by Congress: the summary is the Congressional Research Service's, the action wording is the clerks', and the subjects are the Library of Congress's. How far it got is read from the actions themselves, taking the most recent one of each kind, so a bill that failed a vote and later passed is shown as having passed. Records come from this bill on Congress.gov and govinfo.gov; cost estimates are the Congressional Budget Office's, and the hearings are the printed hearings GovInfo publishes, which can appear months after the hearing.
